IBDEI1TE ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31983,1,4,0)
 ;;=4^I71.2
 ;;^UTILITY(U,$J,358.3,31983,2)
 ;;=^5007787
 ;;^UTILITY(U,$J,358.3,31984,0)
 ;;=I71.4^^182^1979^1
 ;;^UTILITY(U,$J,358.3,31984,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31984,1,3,0)
 ;;=3^Abdominal Aortic Aneurysm w/o Rupture
 ;;^UTILITY(U,$J,358.3,31984,1,4,0)
 ;;=4^I71.4
 ;;^UTILITY(U,$J,358.3,31984,2)
 ;;=^5007789
 ;;^UTILITY(U,$J,358.3,31985,0)
 ;;=I73.9^^182^1979^19
 ;;^UTILITY(U,$J,358.3,31985,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31985,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,31985,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,31985,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,31986,0)
 ;;=I82.891^^182^1979^14
 ;;^UTILITY(U,$J,358.3,31986,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31986,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Chronic
 ;;^UTILITY(U,$J,358.3,31986,1,4,0)
 ;;=4^I82.891
 ;;^UTILITY(U,$J,358.3,31986,2)
 ;;=^5007939
 ;;^UTILITY(U,$J,358.3,31987,0)
 ;;=I82.890^^182^1979^13
 ;;^UTILITY(U,$J,358.3,31987,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31987,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Acute
 ;;^UTILITY(U,$J,358.3,31987,1,4,0)
 ;;=4^I82.890
 ;;^UTILITY(U,$J,358.3,31987,2)
 ;;=^5007938
 ;;^UTILITY(U,$J,358.3,31988,0)
 ;;=E78.0^^182^1980^10
 ;;^UTILITY(U,$J,358.3,31988,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31988,1,3,0)
 ;;=3^Pure Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,31988,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,31988,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,31989,0)
 ;;=E78.1^^182^1980^11
 ;;^UTILITY(U,$J,358.3,31989,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31989,1,3,0)
 ;;=3^Pure Hyperglyceridemia
 ;;^UTILITY(U,$J,358.3,31989,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,31989,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,31990,0)
 ;;=E78.2^^182^1980^9
 ;;^UTILITY(U,$J,358.3,31990,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31990,1,3,0)
 ;;=3^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,31990,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,31990,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,31991,0)
 ;;=I10.^^182^1980^1
 ;;^UTILITY(U,$J,358.3,31991,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31991,1,3,0)
 ;;=3^Essential Primary Hypertension
 ;;^UTILITY(U,$J,358.3,31991,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,31991,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,31992,0)
 ;;=I11.9^^182^1980^8
 ;;^UTILITY(U,$J,358.3,31992,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31992,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,31992,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,31992,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,31993,0)
 ;;=I11.0^^182^1980^7
 ;;^UTILITY(U,$J,358.3,31993,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31993,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,31993,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,31993,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,31994,0)
 ;;=I12.0^^182^1980^6
 ;;^UTILITY(U,$J,358.3,31994,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31994,1,3,0)
 ;;=3^Hypertensive Chr Kidney Disease w/ ESRD
 ;;^UTILITY(U,$J,358.3,31994,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,31994,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,31995,0)
 ;;=I13.10^^182^1980^4
 ;;^UTILITY(U,$J,358.3,31995,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31995,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,31995,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,31995,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,31996,0)
 ;;=I13.0^^182^1980^2
 ;;^UTILITY(U,$J,358.3,31996,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31996,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/ Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;
 ;;$END ROU IBDEI1TE
